SITC's Cancer Immunotherapy Guidelines program is a collection of Clinical Practice Guidelines (CPGs) developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent, and balanced. CPGs will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, among other topics.
The recommendations in the nonmelanoma skin cancer clinical practice guideline provide a valuable clinical decision-making tool to help guide oncologists and other advanced practice providers in the treatment of patients with nonmelanoma skin cancer (NMSC). Topics include selection of appropriate immunotherapeutic regimens, recognition and management of adverse events, and patient quality of life considerations. The manuscript, the latest in the ongoing series of SITC Cancer Immunotherapy Guidelines, is available now in the Journal for ImmunoTherapy of Cancer (JITC), the society’s open access, peer-reviewed online journal.